Helicobacter pylori (H.Pylori) eradication reduces the risk of peptic ulcer recurrence, gastric cancer, and persistent dyspepsia. In Australia, the most commonly used first-line regimen is Nexium HP7 (esomeprazole, amoxicillin, and clarithromycin) for 7 days. While this achieves good cure rates, up to 20–30% of patients may remain positive due to antibiotic resistance, adherence issues, or other risk factors.
Confirming treatment failure
Before re-treatment, confirm persistent H.Pylori infection with a reliable test such as a urea breath test or stool antigen, performed at least 4 weeks after antibiotics and 2 weeks after stopping PPI therapy. Serology is not useful post-treatment.
Next Steps
- Review adherence and risk factors: Missed doses, incomplete therapy, smoking, or ongoing NSAID use can contribute to failure.
- Avoid repeating clarithromycin: If Nexium HP7 has failed, clarithromycin resistance is likely and the same regimen should not be reused.
- Prescribe second-line therapy
We asked Dr Tin Nguyen what he would use as second line therapy. He recommends either of the following options. Both options will need to be ordered through a compounding pharmacy.
1. Levofloxacin triple therapy (10-14 days):
- PPI (e.g. esomeprazole 20 mg) twice daily
- Levofloxacin 500 mg twice daily
- Amoxicillin 1g twice daily
Please note : Avoid levofloxacin if history of tendinopathy, as this is a rare side effect.
2. Bismuth quadruple therapy (10–14 days):
- PPI (e.g. esomeprazole 20 mg) twice daily
- Bismuth subcitrate 120 mg four times daily
- Tetracycline 500 mg four times daily
- Metronidazole 400 mg three times daily
For persistent or complex cases, referral to a gastroenterologist for consideration of culture-guided therapy or endoscopic evaluation.
